Powered by

Pfizer Reports Second-Quarter 2020 Results

Jul 28, 2020 - Nasdaq
Product Launch

Second-Quarter 2020 Revenues of $11.8 Billion , Reflecting 9% Operational Decline; Excluding the Impact from Consumer Healthcare (1), Revenues Declined 3% Operationally 6% Operational Growth from Biopharma, Primarily Driven by Vyndaqel/Vyndamax, Eliquis, Ibrance, Inlyta and Xtandi 31% Operational Decline from Upjohn, Primarily Due to U.S. Loss of Exclusivity of Lyrica in 2019, Partially Offset by 17% Operational Growth in China , Primarily Due to Lipitor and Norvasc Second-Quarter 2020 Report...